All Publications

Data provided by UCSF Profiles, powered by CTSI at UCSF
  1. Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Chen A, Roberts MS, Ward LM. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level. J Clin Endocrinol Metab. 2023 10 18; 108(11):2990-2998. View in PubMed
  2. Weber TJ, Imel EA, Carpenter TO, Peacock M, Portale AA, Hetzer J, Merritt JL, Insogna K. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2022 12 17; 108(1):155-165. View in PubMed
  3. Brandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K, Ito N, Javaid K, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Portale A, Ralston SH, Tanaka H, Weber TJ, Yoo HW, Sun W, Williams A, Nixon A, Takeuchi Y. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif Tissue Int. 2022 10; 111(4):409-418. View in PubMed
  4. Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2022 07 14; 107(8):e3241-e3253. View in PubMed
  5. Hanudel MR, Laster ML, Portale AA, Dokras A, Quigley RP, Guzman GAL, Zaritsky JJ, Hayde NA, Kaskel FJ, Mitsnefes MM, Ramirez JA, Imani PD, Srivaths PR, Kogon AJ, Denburg MR, Blydt-Hansen TD, Reyes LZ, Greenbaum LA, Weidemann DK, Warady BA, Elashoff DA, Mendley SR, Isakova T, Salusky IB. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatr Nephrol. 2022 11; 37(11):2547-2557. View in PubMed
  6. Linglart A, Imel EA, Whyte MP, Portale AA, Högler W, Boot AM, Padidela R, Van't Hoff W, Gottesman GS, Chen A, Skrinar A, Scott Roberts M, Carpenter TO. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. J Clin Endocrinol Metab. 2022 02 17; 107(3):813-824. View in PubMed
  7. Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021 09; 7(3). View in PubMed
  8. Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Williams A, Nixon A, Sun W, Chen A, Skrinar A, Imel EA. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcif Tissue Int. 2021 05; 108(5):622-633. View in PubMed
  9. Yokoyama JS, Matsuda-Abedini M, Denburg MR, Kumar J, Warady BA, Furth SL, Hooper SR, Portale AA, Perwad F. Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study. Kidney Med. 2020 Jul-Aug; 2(4):398-406. View in PubMed
  10. Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. J Bone Miner Res. 2019 12; 34(12):2183-2191. View in PubMed
  11. Perwad F, Portale AA. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD. Clin J Am Soc Nephrol. 2019 07 05; 14(7):1097-1099. View in PubMed
  12. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int. 2019 Sep; 105(3):271-284. View in PubMed
  13. Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 06 15; 393(10189):2416-2427. View in PubMed
  14. Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. Pediatr Nephrol. 2019 Apr; 34(4):739-740. View in PubMed
  15. Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. Pediatr Nephrol. 2019 01; 34(1):145-154. View in PubMed
  16. Altemose KE, Kumar J, Portale AA, Warady BA, Furth SL, Fadrowski JJ, Atkinson MA. Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease. Pediatr Nephrol. 2018 11; 33(11):2131-2136. View in PubMed
  17. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 08; 33(8):1383-1393. View in PubMed
  18. Sgambat K, Roem J, Mitsnefes M, Portale AA, Furth S, Warady B, Moudgil A. Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease. Pediatr Nephrol. 2018 09; 33(9):1577-1583. View in PubMed
  19. Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, Padidela R, Van't Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018 05 24; 378(21):1987-1998. View in PubMed
  20. Ng DK, Portale AA, Furth SL, Warady BA, Muñoz A. Time-varying coefficient of determination to quantify the explanatory power of biomarkers on longitudinal GFR among children with chronic kidney disease. Ann Epidemiol. 2018 08; 28(8):549-556. View in PubMed
  21. Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primers. 2017 Dec 21; 3:17101. View in PubMed
  22. Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol. 2018 01 06; 13(1):45-52. View in PubMed
  23. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016 11 07; 11(11):1989-1998. View in PubMed
  24. Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep. 2016 Dec; 5:158-162. View in PubMed
  25. McEnhill ME, Brennan JL, Winnicki E, Lee MM, Tavakol M, Posselt AM, Stock PG, Portale AA. Effect of Immigration Status on Outcomes in Pediatric Kidney Transplant Recipients. Am J Transplant. 2016 06; 16(6):1827-33. View in PubMed
  26. Portale AA, Zhang MY, David V, Martin A, Jiao Y, Gu W, Perwad F. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. PLoS One. 2015; 10(11):e0142924. View in PubMed
  27. Kumar J, McDermott K, Abraham AG, Friedman LA, Johnson VL, Kaskel FJ, Furth SL, Warady BA, Portale AA, Melamed ML. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort. Pediatr Nephrol. 2016 Jan; 31(1):121-9. View in PubMed
  28. Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol. 2016 Feb; 56(2):176-85. View in PubMed
  29. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016 Feb; 27(2):543-50. View in PubMed
  30. Ku E, Glidden DV, Hsu CY, Portale AA, Grimes B, Johansen KL. Association of Body Mass Index with Patient-Centered Outcomes in Children with ESRD. J Am Soc Nephrol. 2016 Feb; 27(2):551-8. View in PubMed
  31. Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015 Jul; 100(7):2565-73. View in PubMed
  32. Ku E, Johansen KL, Portale AA, Grimes B, Hsu CY. State level variations in nephrology workforce and timing and incidence of dialysis in the United States among children and adults: a retrospective cohort study. BMC Nephrol. 2015 Jan 15; 16:2. View in PubMed
  33. Wassner SJ, Chesney RW, Friedman A, Chantler C, Portale AA. Malcolm A. Holliday, M.D, January 12, 1924 - March 26, 2014. Pediatr Nephrol. 2014 Aug; 29(8):1473-4. View in PubMed
  34. Akber A, Portale AA, Johansen KL. Use of pedometers to increase physical activity among children and adolescents with chronic kidney disease. Pediatr Nephrol. 2014 Aug; 29(8):1395-402. View in PubMed
  35. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014 Feb; 9(2):344-53. View in PubMed
  36. Chanakul A, Zhang MY, Louw A, Armbrecht HJ, Miller WL, Portale AA, Perwad F. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One. 2013; 8(9):e72816. View in PubMed
  37. Benedict KA, Moassesfar S, Adi S, Gitelman SE, Brennan JL, McEnhill M, Stock PG, Portale AA, Posselt AM. Combined pancreatic islet and kidney transplantation in a child with unstable type 1 diabetes and end-stage renal disease. Am J Transplant. 2013 Aug; 13(8):2207-10. View in PubMed
  38. Park-Sigal J, Don BR, Porzig A, Recker R, Griswold V, Sebastian A, Duh QY, Portale AA, Shoback D, Schambelan M. Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone. J Bone Miner Res. 2013 Mar; 28(3):700-8. View in PubMed
  39. Chaudhuri A, Ozawa M, Everly MJ, Ettenger R, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Li L, Sigdel TK, Hsieh SC, Dai H, Naesens M, Waskerwitz J, Salvatierra O, Terasaki PI, Sarwal MM. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol. 2013 Mar; 24(4):655-64. View in PubMed
  40. Li L, Khatri P, Sigdel TK, Tran T, Ying L, Vitalone MJ, Chen A, Hsieh S, Dai H, Zhang M, Naesens M, Zarkhin V, Sansanwal P, Chen R, Mindrinos M, Xiao W, Benfield M, Ettenger RB, Dharnidharka V, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Davis R, Butte AJ, Salvatierra O, Sarwal MM. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant. 2012 Oct; 12(10):2710-8. View in PubMed
  41. Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Tang L, Liu J, Li L, Naesens M, Sigdel T, Waskerwitz J, Salvatierra O. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant. 2012 Oct; 12(10):2719-29. View in PubMed
  42. Akber A, Portale AA, Johansen KL. Pedometer-assessed physical activity in children and young adults with CKD. Clin J Am Soc Nephrol. 2012 May; 7(5):720-6. View in PubMed
  43. Zhang MY, Ranch D, Pereira RC, Armbrecht HJ, Portale AA, Perwad F. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology. 2012 Apr; 153(4):1806-16. View in PubMed
  44. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol. 2011 Dec 05; 347(1-2):17-24. View in PubMed
  45. Ranch D, Zhang MY, Portale AA, Perwad F. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res. 2011 Aug; 26(8):1883-90. View in PubMed
  46. McKay CP, Portale A. Emerging topics in pediatric bone and mineral disorders 2008. Semin Nephrol. 2009 Jul; 29(4):370-8. View in PubMed
  47. Nguyen S, McCulloch C, Brakeman P, Portale A, Hsu CY. Being overweight modifies the association between cardiovascular risk factors and microalbuminuria in adolescents. Pediatrics. 2008 Jan; 121(1):37-45. View in PubMed
  48. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007 Nov; 293(5):F1577-83. View in PubMed
  49. Kim CJ, Kaplan LE, Perwad F, Huang N, Sharma A, Choi Y, Miller WL, Portale AA. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab. 2007 Aug; 92(8):3177-82. View in PubMed
  50. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006 Aug; 91(8):3144-9. View in PubMed
  51. Matsuda-Abedini M, Portale AA, Shah A, Neuhaus J, McEnhill M, Mathias RS. Persistent secondary hyperparathyroidism after renal transplantation in children. Pediatr Nephrol. 2006 Mar; 21(3):413-8. View in PubMed
  52. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005 Dec; 146(12):5358-64. View in PubMed
  53. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005 May 05; 352(18):1884-90. View in PubMed
  54. Azam N, Zhang MY, Wang X, Tenenhouse HS, Portale AA. Disordered regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (hyp) mice. Endocrinology. 2003 Aug; 144(8):3463-8. View in PubMed
  55. Miller WL, Portale AA. Vitamin D biosynthesis and vitamin D 1 alpha-hydroxylase deficiency. Endocr Dev. 2003; 6:156-74. View in PubMed
  56. Wang X, Zhang MY, Miller WL, Portale AA. Novel gene mutations in patients with 1alpha-hydroxylase deficiency that confer partial enzyme activity in vitro. J Clin Endocrinol Metab. 2002 Jun; 87(6):2424-30. View in PubMed
  57. Xie Z, Munson SJ, Huang N, Portale AA, Miller WL, Bikle DD. The mechanism of 1,25-dihydroxyvitamin D(3) autoregulation in keratinocytes. J Biol Chem. 2002 Oct 04; 277(40):36987-90. View in PubMed
  58. Zhang MY, Wang X, Wang JT, Compagnone NA, Mellon SH, Olson JL, Tenenhouse HS, Miller WL, Portale AA. Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1alpha-hydroxylase gene expression in the proximal renal tubule. Endocrinology. 2002 Feb; 143(2):587-95. View in PubMed
  59. Miller WL, Portale AA. Genetics of vitamin D biosynthesis and its disorders. Best Pract Res Clin Endocrinol Metab. 2001 Mar; 15(1):95-109. View in PubMed
  60. Tenenhouse HS, Martel J, Gauthier C, Zhang MY, Portale AA. Renal expression of the sodium/phosphate cotransporter gene, Npt2, is not required for regulation of renal 1 alpha-hydroxylase by phosphate. Endocrinology. 2001 Mar; 142(3):1124-9. View in PubMed
  61. Miller WL, Portale AA. Vitamin D 1 alpha-hydroxylase. Trends Endocrinol Metab. 2000 Oct; 11(8):315-9. View in PubMed
  62. Portale AA, Miller WL. Human 25-hydroxyvitamin D-1alpha-hydroxylase: cloning, mutations, and gene expression. Pediatr Nephrol. 2000 Jul; 14(7):620-5. View in PubMed
  63. Goodman WG, Misra S, Veldhuis JD, Portale AA, Wang HJ, Ament ME, Salusky IB. Altered diurnal regulation of blood ionized calcium and serum parathyroid hormone concentrations during parenteral nutrition. Am J Clin Nutr. 2000 Feb; 71(2):560-8. View in PubMed
  64. Miller WL, Portale AA. Genetic disorders of vitamin D biosynthesis. Endocrinol Metab Clin North Am. 1999 Dec; 28(4):825-40, x. View in PubMed
  65. Miller WL, Portale AA. Genetic causes of rickets. Curr Opin Pediatr. 1999 Aug; 11(4):333-9. View in PubMed
  66. Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 1999 Jul; 56(1):268-74. View in PubMed
  67. Wang JT, Lin CJ, Burridge SM, Fu GK, Labuda M, Portale AA, Miller WL. Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Am J Hum Genet. 1998 Dec; 63(6):1694-702. View in PubMed
  68. Portale AA, Miller WL. Hereditary rickets revealed. Kidney Int. 1998 Nov; 54(5):1762-4. View in PubMed
  69. Mathias RS, Nguyen HT, Zhang MY, Portale AA. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J Am Soc Nephrol. 1998 Nov; 9(11):2067-74. View in PubMed
  70. Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, Portale AA. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol. 1997 Dec; 11(13):1961-70. View in PubMed
  71. Fu GK, Portale AA, Miller WL. Complete structure of the human gene for the vitamin D 1alpha-hydroxylase, P450c1alpha. DNA Cell Biol. 1997 Dec; 16(12):1499-507. View in PubMed
  72. Portale AA, Lonergan ET, Tanney DM, Halloran BP. Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. Am J Physiol. 1997 Jan; 272(1 Pt 1):E139-46. View in PubMed
  73. Halloran BP, Lonergan ET, Portale AA. Aging and renal responsiveness to parathyroid hormone in healthy men. J Clin Endocrinol Metab. 1996 Jun; 81(6):2192-7. View in PubMed
  74. Portale AA, Halloran BP, Morris RC, Lonergan ET. Effect of aging on the metabolism of phosphorus and 1,25-dihydroxyvitamin D in healthy men. Am J Physiol. 1996 Mar; 270(3 Pt 1):E483-90. View in PubMed
  75. Quan A, Portale A, Foster S, Lavine J. Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplantation. Pediatr Nephrol. 1995 Oct; 9(5):599-602. View in PubMed
  76. Sorof JM, Koerper MA, Portale AA, Potter D, DeSantes K, Cowan M. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation. 1995 Jun 15; 59(11):1633-5. View in PubMed
  77. Sorof JM, Weidner N, Potter D, Portale AA. Acute post-streptococcal glomerulonephritis in a renal allograft. Pediatr Nephrol. 1995 Jun; 9(3):317-9. View in PubMed
  78. Portale AA, Halloran BP, Harris ST, Bikle DD, Morris RC. Metabolic acidosis reverses the increase in serum 1,25(OH)2D in phosphorus-restricted normal men. Am J Physiol. 1992 12; 263(6):E1164-70. View in PubMed
  79. Bikle DD, Halloran BP, Harris ST, Portale AA. Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab. 1992 Aug; 75(2):519-23. View in PubMed
  80. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991 May; 72(5):1130-5. View in PubMed
  81. Potter DE, Portale AA, Melzer JS, Feduska NJ, Garovoy MR, Husing RM, Salvatierra O. Are blood transfusions beneficial in the cyclosporine era? Pediatr Nephrol. 1991 Jan; 5(1):168-72. View in PubMed
  82. Portale AA, Morris RC. Pathogenesis of secondary hyperparathyroidism in chronic renal insufficiency. Miner Electrolyte Metab. 1991; 17(4):211-20. View in PubMed
  83. Sebastian A, Hernandez RE, Portale AA, Colman J, Tatsuno J, Morris RC. Dietary potassium influences kidney maintenance of serum phosphorus concentration. Kidney Int. 1990 May; 37(5):1341-9. View in PubMed
  84. Halloran BP, Portale AA, Lonergan ET, Morris RC. Production and metabolic clearance of 1,25-dihydroxyvitamin D in men: effect of advancing age. J Clin Endocrinol Metab. 1990 Feb; 70(2):318-23. View in PubMed
  85. Portale AA, Halloran BP, Morris RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989 May; 83(5):1494-9. View in PubMed
  86. Farine D, Jackson U, Portale A, Baxi L, Fox HE. Pregnancy complicated by maternal spina bifida. A report of two cases. J Reprod Med. 1988 Mar; 33(3):323-6. View in PubMed
  87. Portale AA, Halloran BP, Morris RC. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest. 1987 Oct; 80(4):1147-54. View in PubMed
  88. Kurtz TW, Portale AA, Morris RC. Evidence for a difference in vitamin D metabolism between spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 1986 Nov; 8(11):1015-20. View in PubMed
  89. Potter DE, San Luis E, Wipfler JE, Portale AA. Comparison of continuous ambulatory peritoneal dialysis and hemodialysis in children. Kidney Int Suppl. 1986 Jul; 19:S11-4. View in PubMed
  90. Kurtz TW, Kabra PM, Booth BE, Al-Bander HA, Portale AA, Serena BG, Tsai HC, Morris RC. Liquid-chromatographic measurements of inosine, hypoxanthine, and xanthine in studies of fructose-induced degradation of adenine nucleotides in humans and rats. Clin Chem. 1986 May; 32(5):782-6. View in PubMed
  91. Chesney RW, Mehls O, Anast CS, Brown E, Hammerman MR, Portale A, Fallon MD, Mahan J, Alfrey AC. Renal osteodystrophy in children: the role of vitamin D, phosphorus, and parathyroid hormone. Am J Kidney Dis. 1986 Apr; 7(4):275-84. View in PubMed
  92. Portale AA, Halloran BP, Murphy MM, Morris RC. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest. 1986 Jan; 77(1):7-12. View in PubMed
  93. Halloran BP, Portale AA, Castro M, Morris RC, Goldsmith RS. Serum concentration of 1,25-dihydroxyvitamin D in the human: diurnal variation. J Clin Endocrinol Metab. 1985 Jun; 60(6):1104-10. View in PubMed
  94. Portale AA, Booth BE, Halloran BP, Morris RC. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984 Jun; 73(6):1580-9. View in PubMed
  95. Powell D, Pond SM, Allen TB, Portale AA. Hemoperfusion in a child who ingested diquat and died from pontine infarction and hemorrhage. J Toxicol Clin Toxicol. 1983 Jul; 20(5):405-20. View in PubMed
  96. Portale AA, Booth BE, Tsai HC, Morris RC. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int. 1982 Apr; 21(4):627-32. View in PubMed
  97. Galvagna S, Rosella PP, Portale A. [Clinical study of the effects of metisoprinol in the treatment of mumps in adults]. Clin Ter. 1980 Dec 31; 95(6):681-5. View in PubMed
  98. Holliday MA, McHenry-Richardson K, Portale A. Nutritional management of chronic renal disease. Med Clin North Am. 1979 Sep; 63(5):945-62. View in PubMed